ST未名 (002581)

Shandong Sinobioway Biomedicine Co., Ltd.

ASZ

Tags

Contract Research Organization (CXO)Special Treatment (ST) SectorInnovative DrugsBroker Heavy PositionsPharmaceutical ManufacturingGene ConceptDecreasing Shareholder CountPlanned Reduction of HoldingsBiological VaccinesBelow Additional Issuance PriceHepatitis ConceptUniversity Background

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 65973.56
  • Circulating A-Shares(W): 40079.12
  • Earnings Per Share(RMB): -0.1043
  • Net Assets Per Share(RMB): 2.8335
  • Operating Revenue(W RMB): 21205.00
  • Total Profit(W RMB): -10259.34
  • Net Profit Attributable to Parent(W RMB): -6881.07
  • Net Profit Growth Rate(%): -570.46
  • Weighted Return on Equity(%): -3.6200
  • Operating Cash Flow Per Share(RMB): -0.3490
  • Undistributed Profit Per Share(RMB): 0.9197
  • Capital Reserve Per Share(RMB): 1.3353

2. Main Business

The main business covers:

  • Interferon, nerve growth factor, vaccines and other biopharmaceutical sectors

3. Company Basic Information

  • Company Name: Shandong Sinobioway Biomedicine Co., Ltd.
  • Listing Date: 2011-05-20
  • Industry: Pharmaceutical Manufacturing
  • Address: 27F, Qimei Building, Intersection of Xinhuan East Road and Rong'er Road, Mashang Sub-district Office, Zhangdian District, Zibo City, Shandong Province
  • Website: www.bioway-pku.com
  • Company Profile: The issuer was approved by the Shandong Provincial Department of Commerce's document "Lu Shang Wai Zi Zi [2009] No. 289" dated October 26, 2009, "Approval on Agreeing to the Transformation of Zibo Wanchang Technology Development Co., Ltd. into a Foreign-invested Joint Stock Limited Company," and was established as a foreign-invested joint stock limited company through the overall change of Wanchang Development. According to the "Audit Report" issued by Daxin Certified Public Accountants, "Da Xin Shen Zi [2009] 3-0364," Wanchang Development converted its audited net assets of RMB 103,970,845.23 as of June 30, 2009, into the company's share capital of RMB 58 million, with the remaining RMB 45,970,845.23 credited to capital reserve. The shareholders subscribed for the company's shares with the net assets corresponding to their respective equity interests in Wanchang Development. Daxin Certified Public Accountants issued the "Capital Verification Report" "Da Xin Yan Zi [2009] 3-0018," confirming that the contributions of all promoters had been made. The issuer was registered with the Shandong Provincial Administration for Industry and Commerce on November 16, 2009, with a registered capital of RMB 58 million, and obtained the "Business License of Enterprise Legal Person" with registration number 370300400000903.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shenwan Hongyuan Securities Co., Ltd. Securities Company 579.00 1.44

5. Concept Sectors

  • ST Sector
  • Biological Vaccine
  • Gene Concept
  • CXO Concept
  • Hepatitis Concept
  • Innovative Drug
  • Securities Firm Heavy Holdings
  • University Background
  • Decreasing Shareholder Number
  • Intended Reduction
  • Below Issue Price

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information